CUDC-427 is primarily investigated for its potential in cancer therapy. It functions as an inhibitor of apoptosis proteins (IAPs), which are often overexpressed in various cancer types, contributing to tumor survival and resistance to treatment. By targeting IAPs, CUDC-427 promotes apoptosis in cancer cells, making it a promising candidate for overcoming drug resistance. It is being studied in preclinical and clinical settings for its efficacy in treating solid tumors and hematologic malignancies. Additionally, its ability to enhance the effects of other anticancer therapies, such as chemotherapy and radiation, is under exploration. Research is ongoing to determine its safety, optimal dosing, and potential combination with other treatments to improve patient outcomes.